Editorial: terlipressin in patients with acute‐on‐chronic liver failure grade 3—too late?
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17244 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, 2023. Written by Jonel Trebicka and 1 co-authors. Institution: Department of Internal Medicine B, University of Münster, Münster, Germany. Major MEDLINE topics: Acute-On-Chronic Liver Failure. Cited 3 times so far (Crossref); 7 references. Funded by: Deutsche Forschungsgemeinschaft.
Abstract (original language)
LINKED CONTENT This article is linked to Wong et al papers. To view these articles, visit https://doi.org/10.1111/apt.17195 and https://doi.org/10.1111/apt.17323
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Internal Medicine B, University of Münster, Münster, Germany.
- European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
- Department of Anesthesiology, Intensive Care and Pain Medicine, University of Münster, Münster, Germany.
ORCID profiles: Jonel Trebicka
Funding
- Deutsche Forschungsgemeinschaft
Cite
APA
Trebicka, J., & Zarbock, A. (2023). Editorial: terlipressin in patients with acute‐on‐chronic liver failure grade 3—too late?. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17244
Vancouver
Trebicka J, Zarbock A. Editorial: terlipressin in patients with acute‐on‐chronic liver failure grade 3—too late?. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17244
BibTeX
@article{Trebicka2023,
author = {Trebicka, Jonel and Zarbock, Alexander},
title = {Editorial: terlipressin in patients with acute‐on‐chronic liver failure grade 3—too late?},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17244}
}
EUVIMED